UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000024045
Receipt number R000027690
Scientific Title The effect of L-glutamine on oral mucositis induced by chemoradiotherapy in patients with head and neck cancer.
Date of disclosure of the study information 2016/10/01
Last modified on 2016/09/14 09:13:53

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The effect of L-glutamine on oral mucositis induced by chemoradiotherapy in patients with head and neck cancer.

Acronym

The effect of L-glutamine on oral mucositis induced by chemoradiotherapy in patients with head and neck cancer.

Scientific Title

The effect of L-glutamine on oral mucositis induced by chemoradiotherapy in patients with head and neck cancer.

Scientific Title:Acronym

The effect of L-glutamine on oral mucositis induced by chemoradiotherapy in patients with head and neck cancer.

Region

Japan


Condition

Condition

Head and neck cancer.

Classification by specialty

Oto-rhino-laryngology Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate of efficacy of enteral supplementation product enriched with L-glutamine in patients with head and neck cancer.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

CTCAE score for inflammation of oral pharyngeal mucosa.

Key secondary outcomes

1)Physical measurement
Body weight, Lean body weight, body fat mass, Grip strength
2)Digestive symptom
oral mucositis, taste disturbance, diarrhea, appetite
3)score of Quality of life(QOL)
EORT-QLQ-C30
4)Blood test
Alb,TP,PA,RBP,serum diamine oxidase activity,IL-6,active ghrelin
5)Amount of total Energy
by oral feeding, enteral feeding, parenteral nutrition
6)Duration and dosage of opioid.
7)Rate of CRT completion.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

L-glutamine group: L-glutamine(1-3 pack per day) from 4days before to end of CRT.

Interventions/Control_2

Control group: Placebo(1-3 pack per day) from 4days before to end of CRT.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Aged >= 20
2) Patients with head and neck cancer.
3) Patients who receive chemoradiotherapy.
4) Recovered from previous chemotherapy and radiotherapy toxicities.
5) Patients who obtained the consent.

Key exclusion criteria

1)Unable intake glutamine formulations per oral or per enteral tube.
2)major impairment of liver
3)major impairment of kidney
4)allergic to L-glutamine
5)pregnant,lactating
6)presence of other cancer under treatment.
7)severe psychosis or psychiatric symptoms
8)paticipation judged by physician to be inadvisable
9)paticipation not taking opioids

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Mika Kurihara

Organization

Shiga University of Medical Science Hospital

Division name

Clinical nutrition

Zip code


Address

Seta Tsukinowa-cho, Otsu-city, Shiga, Japan 520-2192

TEL

077-548-2519

Email

kuri@belle.shiga-med.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Mai Inoue

Organization

Shiga University of Medical Science Hospital

Division name

Clinical nutrition

Zip code


Address

Seta Tsukinowa-cho, Otsu-city, Shiga, Japan 520-2192

TEL

077-548-2519

Homepage URL


Email

maiapril@belle.shiga-med.ac.jp


Sponsor or person

Institute

Shiga University of Medical Science Hospital

Institute

Department

Personal name



Funding Source

Organization

Aido Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 10 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Date of protocol fixation

2016 Year 11 Month 01 Day

Date of IRB


Anticipated trial start date

2016 Year 11 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 09 Month 14 Day

Last modified on

2016 Year 09 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027690


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name